Chronix’s new liquid biopsy approach show promise as early predictor of cancer therapies

A blood-based test which looks at chromosomal gains and losses in cell-free DNA (cfDNA) has demonstrated its potential of being a predictor of how well cancer patients are responding to chemotherapy.